Palisade Bio Reports First Quarter 2023 Financial Results
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE…
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE…
LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) (the Company,…
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time YAVNE,…
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022…
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider…
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels…
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company…
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris…
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left…
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of…
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned…
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets…
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include…
Record first quarter 2023 consolidated revenue of $33.1 million, up 14% from the same year-ago…
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma…
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across…